Disease · MONDO_0024462

susceptibility to familial cutaneous melanoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. susceptibility to familial cutaneous melanoma. Diseases, record MONDO_0024462. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024462

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: susceptibility to familial cutaneous melanoma
Open Targets ID: MONDO_0024462
Other names: hereditary cutaneous melanoma (disease), melanoma, cutaneous malignant
Highest stage of its drugs: Phase 3, for 4 of its 6 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
INTERFERON ALFA	CHEMBL2108506	Protein	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
INTERFERON ALFA-2A	CHEMBL2108508	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BINIMETINIB	CHEMBL3187723	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TISLELIZUMAB	CHEMBL4297840	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3455	Drugs and targets
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	1	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	1	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor	Phase 2	https://conductscience.org/library/genes/5605	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01320085	A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma	Phase 2	183	2021-01-05	BRAF or NRAS Mutant Metastatic Melanoma	BINIMETINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06488482	Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma	Phase 3	1,792		High-risk Melanoma	NIVOLUMAB, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00002892	Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma	Phase 3	1,000		Melanoma (Skin)	INTERFERON ALFA-2A	Open Targets' reading of its record	ClinicalTrials.gov
NCT05479812	Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors	Phase 1	156		Metastatic Solid Tumor, Advanced Solid Tumor	PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04924413	L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma	Phase 2	9		Malignant Melanoma	TISLELIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36856617	RESULT	1	PubMed
35367007	RESULT	1	PubMed
32961119	RESULT	1	PubMed
29658430	RESULT	1	PubMed
23957516	RESULT	1	PubMed
14665609	RESULT	1	PubMed
41896823	DERIVED	1	PubMed
23414587	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0024462

GET https://conductscience.org/api/diseases/v1/MONDO_0024462/drugs

API reference For AI assistants